Aim: Covid-19 (Coronavirus disease 2019) is a disease that has already taken place in human history. Although there is still no effective treatment and vaccine protocol, different treatment options are being tried. In this study, it was aimed to determine the basic characteristics and changes in laboratory findings of patients who were hospitalized with the diagnosis of Covid-19 in the intensive care unit and underwent treatment protocol containing favipiravir.
Material and Method: It was carried out with the data of 179 inpatients in an intensive care unit between 01.06.2020 - 30.06.2020. The inclusion criterias of the study are to have a diagnosis of COVID-19 confirmed by PCR test, to be hospitalized in the intensive care unit, receiving therapy combined with favipravir and to have access to its data through the automation system. According to literature; the sociodemographic characteristics, some basic characteristics and some laboratory findings of the patients were evaluated. Statistical analyzes were performed using the Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp .; Armonk, NY, USA).
Findings: The average age of the study group is 60.9±16.4 years and 65.9% (n:118) of them are male. According to the clinical classification, more than half (50.8%, n: 91) are included in the "high" clinical classification. The most common chronic disease is "hypertension (HT)" (42.5%, n:76) and the most common symptom is "fever" (57.5%, n: 103). While 82.7% (n: 148) have widespread CT (Computed tomography) findings, CPR (C-Reactive protein) positivity rate is 65.4% (n: 117). Statistical significant difference was detected between three measurements of blood urea nitrogen (BUN), aspartat aminotransferase (AST), alanin aminotransfrase (ALT), CRP between the 1st and the 3rd day.
Conclusion: Favipiravir demonstrates a proper safety profile. However, its side effects teratogenicity, hyperuricaemia and QTc (corrected QT interval) prolongation have not yet been adequately studied. It may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment.
Key words: Covid-19, favipravir, laboratory findings, treatment, side effect
|
